NCT06512467尚未招募2 期
Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 30
- 主要终点
- MPR(Major Pathological Response)
研究概览
简要总结
The investigators design a phase IIB clinical study to explore the efficacy and safety of Donafenib combined with Sintilimab and HAIC in neoadjuvant of resectable Hepatocellular Carcinoma.
详细描述
This trial is a single-arm, non-randomized and single-center clinical study of Donafenib combined with Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular CarcinomaIt will estimate that 30 patients who met the study criteria will be enrolled in Tianjin Medical University Cancer Institute and Hospital and neoadjuvant in Donafenib combined with Sintilimab and HAIC. The investigators will follow up and collect subjects' data monthly to evaluate the efficacy and safety of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily join the study and sign the informed consent;
- •Age 18 ~ 80 years old (including 80 years old), male and female;
- •Patients with hepatohcellular carcinoma diagnosed clinically or confirmed by histology / cytology according to the code for diagnosis and treatment of primary liver cancer (2022 Edition);
- •Hepatocellular carcinoma and technically resectable (CNLC stage Ⅱb to Ⅲa), estimated residual liver volume >30%, in patients with cirrhosis, the residual liver volume is >40%. And meets at least one of the following conditions:
- •The tumor is adjacent to large blood vessels or other organs, resulting in an expected surgical margin of less than 1cm;
- •Cancer thrombus formation was associated with ipsilateral portal vein or hepatic vein, but the tumor thrombus did not accumulate in the main contralateral portal vein, contralateral portal vein, contralateral hepatic vein, and superior mesenteric vein;
- •At least one assessable lesion (mRECIST criteria),and did not receive radiotherapy or local treatmen;
- •ECOG 0 ~ 1;
- •Major organs are functioning normally. Hemoglobin ≥ 90 g / L; ANC ≥ 1.5 × 109/L； Platelet count ≥ 100 × 109/L； Albumin ≥ 28 g / L; Total bilirubin ≤ 3 × ULN; AST, ALT ≤ 5 × ULN； TSH ≤ ULN； INR or PT ≤ 1.5 × ULN, APTT ≤ ULN.
- •If HBsAg (+) and/or anti-HCV (+), antiviral therapy should be standard based on HBV DNA or HCV RNA test results;
- •Be able to cooperate to observe adverse events. -
排除标准
- •Cholangiocarcinoma, mixed cell carcinoma and fibrous laminar cell carcinoma are known
- •Diffuse tumor lesions
- •extrahepatic metastasis
- •Active malignancies other than HCC occur within 5 years or at the same time, with the exception of cured skin basal cell carcinoma, cervical carcinoma in situ and thyroid form carcinoma;
- •Received radical hepatectomy, systemic anticancer therapy for liver cancer (mainly including systemic chemotherapy, molecular targeted therapy, CTLA-4, PD-1/PD-L1 monoclonal antibody immunotherapy) and local liver therapy, including TACE, HAIC, TAE, local ablation, radiotherapy, etc;
- •The following conditions were present during the course of the study: myocardial infarction, severe unstable angina pectoris, NYHA2 or higher cardiac insufficiency, poor arrhythmia control, symptomatic congestive heart failure, cerebrovascular accident;
- •A history of hypertensive crisis or hypertensive encephalopathy;
- •The subject has any history of active autoimmune disease or autoimmune disease (but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitaritis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; Subjects with vitiligo or childhood asthma are in complete remission and can be included as adults without any intervention; Asthma requiring medical intervention with bronchodilators will not be included);
- •Subjects are receiving immunosuppressive, systemic or absorbable local hormone therapy for immunosuppressive purposes and continue to receive such therapy during the 2 weeks prior to enrollment;
- •Abnormal coagulation (INR > 1.5 or APTT > 1.5 x ULN) with bleeding tendency or receiving thrombolysis or anticoagulation therapy;
- •Known severe adverse reactions to Donafenib, sindillizumab, or severe allergic reactions to other monoclonal antibodies;
- •The subject has a known history of psychotropic, alcohol, or drug abuse. -
研究组 & 干预措施
Donafenib combined with Sintilimab and HAIC
Experimental
Donafenib:200mg bid; Sintilimab:200mg Q3D; HAIC:Q3W.
干预措施: Donafenib (Drug)
Donafenib combined with Sintilimab and HAIC
Experimental
Donafenib:200mg bid; Sintilimab:200mg Q3D; HAIC:Q3W.
干预措施: Sintilimab (Drug)
Donafenib combined with Sintilimab and HAIC
Experimental
Donafenib:200mg bid; Sintilimab:200mg Q3D; HAIC:Q3W.
干预措施: HAIC (Other)
结局指标
主要结局
MPR(Major Pathological Response)
时间窗: 1 year
After neoadjuvant therapy, the proportion of residual tumor cells was less than 30%.
次要结局
- ORR(Objective Response Rate)(1 year)
- OS(Overall Survival)(3 year)
- RFS(Recurrence-free Survival)(1 year)
- DCR(Disease Control Rate)(3 year)
- pCR(Pathological Complete Response)(1 year)
研究者
相似试验
尚未招募
2 期
Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaNCT05166772Tianjin Medical University Cancer Institute and Hospital30
尚未招募
2 期
Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular CarcinomaHepatocellular CarcinomaNCT05161143Peking Union Medical College Hospital30
已完成
2 期
Donafenib Plus Sintilimab for Advanced HCCHepatocellular CarcinomaNCT05162352Second Affiliated Hospital of Guangzhou Medical University30
进行中（未招募）
2 期
Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular CarcinomaUnresectable Hepatocellular CarcinomaNCT05507632Nanfang Hospital, Southern Medical University48
尚未招募
4 期
Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous TherapyUnresectable Hepatocellular CarcinomaNCT06496815Tongji Hospital32